These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

422 related articles for article (PubMed ID: 25349643)

  • 1. Targeting the insulin-like growth factor pathway in hepatocellular carcinoma.
    Enguita-Germán M; Fortes P
    World J Hepatol; 2014 Oct; 6(10):716-37. PubMed ID: 25349643
    [TBL] [Abstract][Full Text] [Related]  

  • 2. IGF2 Is Up-regulated by Epigenetic Mechanisms in Hepatocellular Carcinomas and Is an Actionable Oncogene Product in Experimental Models.
    Martinez-Quetglas I; Pinyol R; Dauch D; Torrecilla S; Tovar V; Moeini A; Alsinet C; Portela A; Rodriguez-Carunchio L; Solé M; Lujambio A; Villanueva A; Thung S; Esteller M; Zender L; Llovet JM
    Gastroenterology; 2016 Dec; 151(6):1192-1205. PubMed ID: 27614046
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epigenetic regulation of insulin-like growth factor axis in hepatocellular carcinoma.
    El Tayebi HM; Abdelaziz AI
    World J Gastroenterol; 2016 Mar; 22(9):2668-77. PubMed ID: 26973407
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatocellular Carcinoma: Etiology and Current and Future Drugs.
    Jindal A; Thadi A; Shailubhai K
    J Clin Exp Hepatol; 2019; 9(2):221-232. PubMed ID: 31024205
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Insulin-like growth factor-1 receptor inhibition induces a resistance mechanism via the epidermal growth factor receptor/HER3/AKT signaling pathway: rational basis for cotargeting insulin-like growth factor-1 receptor and epidermal growth factor receptor in hepatocellular carcinoma.
    Desbois-Mouthon C; Baron A; Blivet-Van Eggelpoël MJ; Fartoux L; Venot C; Bladt F; Housset C; Rosmorduc O
    Clin Cancer Res; 2009 Sep; 15(17):5445-56. PubMed ID: 19706799
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Emerging role of insulin-like growth factor-binding protein 7 in hepatocellular carcinoma.
    Akiel M; Rajasekaran D; Gredler R; Siddiq A; Srivastava J; Robertson C; Jariwala NH; Fisher PB; Sarkar D
    J Hepatocell Carcinoma; 2014; 1():9-19. PubMed ID: 27508172
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of insulin-like growth factor 2, insulin-like growth factor receptor 2, insulin receptor substrate 2 genes polymorphisms on susceptibility and clinicopathological features of hepatocellular carcinoma.
    Rashad NM; El-Shal AS; Abd Elbary EH; Abo Warda MH; Hegazy O
    Cytokine; 2014 Jul; 68(1):50-8. PubMed ID: 24656929
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evolving therapies in the treatment of hepatocellular carcinoma.
    Spangenberg HC; Thimme R; Blum HE
    Biologics; 2008 Sep; 2(3):453-62. PubMed ID: 19707376
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A pleiotropic effect of the single clustered hepatic metastamiRs miR-96-5p and miR-182-5p on insulin-like growth factor II, insulin-like growth factor-1 receptor and insulin-like growth factor-binding protein-3 in hepatocellular carcinoma.
    Assal RA; El Tayebi HM; Hosny KA; Esmat G; Abdelaziz AI
    Mol Med Rep; 2015 Jul; 12(1):645-50. PubMed ID: 25739014
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of insulin-like growth factor 1 receptor enhances the efficacy of sorafenib in inhibiting hepatocellular carcinoma cell growth and survival.
    Wang F; Bank T; Malnassy G; Arteaga M; Shang N; Dalheim A; Ding X; Cotler SJ; Denning MF; Nishimura MI; Breslin P; Qiu W
    Hepatol Commun; 2018 Jun; 2(6):732-746. PubMed ID: 29881824
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum from Chronic Hepatitis B Patients Promotes Growth and Proliferation via the IGF-II/IGF-IR/MEK/ERK Signaling Pathway in Hepatocellular Carcinoma Cells.
    Ji Y; Wang Z; Chen H; Zhang L; Zhuo F; Yang Q
    Cell Physiol Biochem; 2018; 47(1):39-53. PubMed ID: 29763915
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IGF-II Producing Hepatocellular Carcinoma Treated with Sorafenib: Metabolic Complications and a Foresight to Molecular Targeting Therapy to the IGF Signal.
    Okushin K; Asaoka Y; Fukuda I; Fujiwara N; Minami T; Sato M; Mikami S; Uchino K; Enooku K; Kondo Y; Tateishi R; Goto T; Shiina S; Yoshida H; Koike K
    Case Rep Gastroenterol; 2012 Sep; 6(3):784-9. PubMed ID: 23341802
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Goals and targets for personalized therapy for HCC.
    Couri T; Pillai A
    Hepatol Int; 2019 Mar; 13(2):125-137. PubMed ID: 30600478
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum insulin-like growth factor-I level is an independent predictor of recurrence and survival in early hepatocellular carcinoma: a prospective cohort study.
    Cho EJ; Lee JH; Yoo JJ; Choi WM; Lee MJ; Cho Y; Lee DH; Lee YB; Kwon JH; Yu SJ; Lee JM; Suh KS; Kim K; Kim YJ; Yoon JH; Kim CY; Lee HS
    Clin Cancer Res; 2013 Aug; 19(15):4218-27. PubMed ID: 23757355
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacogenetics of the systemic treatment in advanced hepatocellular carcinoma.
    De Mattia E; Cecchin E; Guardascione M; Foltran L; Di Raimo T; Angelini F; D'Andrea M; Toffoli G
    World J Gastroenterol; 2019 Aug; 25(29):3870-3896. PubMed ID: 31413525
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum Insulin-Like Growth Factor-1 (IGF-1): a Novel Prognostic Factor for Early Recurrence of Hepatocellular Carcinoma (HCC).
    Yao Y; Mao W; Dong M; Yang D; Li W; Chen Y
    Clin Lab; 2017 Feb; 63(2):261-270. PubMed ID: 28182337
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adjuvant therapy for hepatocellular carcinoma: current situation and prospect.
    Wang Z; Zhang G; Wu J; Jia M
    Drug Discov Ther; 2013 Aug; 7(4):137-43. PubMed ID: 24071575
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Insulin-like growth factor (IGF)-signalling pathway components are potential therapeutic targets in the treatment of human hepatocellular carcinoma].
    Nussbaum T; Samarin J; Schirmacher P; Breuhahn K
    Verh Dtsch Ges Pathol; 2007; 91():278-85. PubMed ID: 18314625
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of hepatocellular carcinoma cell growth by an anti-insulin-like growth factor-I receptor monoclonal antibody.
    Yue L; Wang Y; Wang H; Gao H; Liang J; Sui A; Xiang J; Zhou F; Xu C; Zhao W; Liang W; Yao R
    Oncol Rep; 2012 Oct; 28(4):1453-60. PubMed ID: 22895605
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Growth factor receptors and related signalling pathways as targets for novel treatment strategies of hepatocellular cancer.
    Höpfner M; Schuppan D; Scherübl H
    World J Gastroenterol; 2008 Jan; 14(1):1-14. PubMed ID: 18176955
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.